Results 121 to 130 of about 524,281 (314)
Use of telemedicine by practising allergists before and during the SARS-CoV-2 pandemic [PDF]
, 2021 Stephanie Dramburg +3 more
openalex +1 more source
Advanced Science, EarlyView.Cryopreserved lung‐humanized mice overcome the dependency to fresh tissues and permit head‐to‐head profiling of all four human common cold coronaviruses versus SARS‐CoV‐2 infection; the model validates Paxlovid efficacy against HKU1 and, when coupled with human immune‐system engraftment, enables interrogation of lung‐resident human immunity and HKU1 ...
Chunyu Cheng +9 more
wiley +1 more source
Crisis Prevention and the Coronavirus Pandemic as a Global and Total Risk of Our Time [PDF]
, 2021 Radoica Luburić
openalex +1 more source
Advanced Science, EarlyView.Current SARS‐CoV‐2 vaccines generate short‐lived, strain‐specific immunity. A polymeric TLR7 agonist nanoparticle (TLR7‐NP) adjuvant enhances lymph node targeting and promotes early and sustained germinal center responses toward conserved S2 epitopes of the spike protein.
Sijin Huang +12 more
wiley +1 more source
Structure‐Based Development of Ultra‐Broad‐Spectrum 3C‐Like Protease Inhibitors
Advanced Science, EarlyView.This study provides an in‐depth analysis of the substrate binding pocket of 3CLpros across all coronavirus species using bioinformatics and structural insights, revealing the critical impact of S2/S4 subsite diversity on the broad‐spectrum activity of approved therapeutics.
Haixia Su +15 more
wiley +1 more source
Understanding the impact of the Covid-19 pandemic through the lens of innovation
, 2021 Shanthi Gopalakrishnan +1 more
openalex +1 more source
The coronavirus disease 2019 pandemic and the rights of the child in Japan [PDF]
, 2021 Arisa Yamaguchi +10 more
openalex +1 more source
A Rationally Engineered Spleen‐Tropic One‐Component Lipid‐mRNA Complex (OncoLRC) for Cancer Vaccines
Advanced Science, EarlyView.OncoLRC, a one‐component lipid‐mRNA complex, enables efficient spleen‐targeted delivery at an exceptionally low lipid‐to‐mRNA mass ratio (1.5:1), robustly activates immune responses, inhibits tumor growth, and synergizes with checkpoint blockade, presenting a next‐generation platform for mRNA vaccines.
Qimeng Yin +4 more
wiley +1 more source